Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 4/20 | 0.47 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | MLNR | O43193 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3604592 | 0.75 | CACNA1G (0.58) | CACNA1GCACNA1HOPRL1HTR4OPRM1 | |
| SCHEMBL4865936 | 0.72 | OPRL1 (0.54) | OPRL1HTR4OPRM1CHRM3OPRK1 | |
| SCHEMBL11509051 | 0.70 | DRD2 (0.55) | CACNA1GCACNA1HOPRL1OPRM1PMP22 | |
| SCHEMBL3617803 | 0.69 | OPRL1 (0.68) | OPRL1OPRM1DRD2DRD4DRD3 | |
| SCHEMBL3615399 | 0.68 | DRD2 (0.51) | OPRL1OPRM1CYP2D6DRD2DRD4 | |
| SCHEMBL3612375 | 0.66 | OPRM1 (0.61) | OPRL1CHRM1OPRM1CHRM2CHRM3 | |
| SCHEMBL3615787 | 0.66 | OPRL1 (0.68) | OPRL1OPRM1 | |
| SCHEMBL24708724 | 0.65 | CACNA1G (1.00) | CACNA1GCACNA1HOPRL1OPRM1CYP2D6 | |
| SCHEMBL30079694 | 0.65 | CACNA1G (1.00) | CACNA1GCACNA1HOPRL1OPRM1CYP2D6 | |
| Hydrochloric Acid SCHEMBL11033286 | 0.65 | HTR4 (0.45) | OPRL1HTR4OPRM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128288-A1 | Useful in the treatment of chronic and acute pain. | PURDUE PHARMA L.P. | 2002-09-12 | — | — | US | claimed |
| US-7678809-B2 | Benzimidazole compounds having nociceptin receptor affinity | PURDUE PHARMA L.P. (US) | 2010-03-16 | — | — | US | disclosed |
| US-7456198-B2 | Useful in the treatment of chronic and acute pain. | PURDUE PHARMA L.P. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20060264638-A1 | Benzimidazole compounds having nociceptin receptor affinity | EURO-CELTIQUE S.A. (LU) | 2006-11-23 | — | — | US | disclosed |
| US-20020128288-A1 | Useful in the treatment of chronic and acute pain. | PURDUE PHARMA L.P. | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264638-A1 | Benzimidazole compounds having nociceptin receptor affinity | OPRL1, OPRK1, OGFRL1 | CACNA1G 902/4885CACNA1H 922/4885OPRL1 1/4885 |
| US-20020128288-A1 | Useful in the treatment of chronic and acute pain. | OPRL1, OGFRL1, OPRK1 | CACNA1G 298/4885CACNA1H 334/4885OPRL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.